Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis

Hengrui Liang
Hengrui Liang
Guo Lin
Guo Lin
Jun Huang
Jun Huang
Yilin Yang
Yilin Yang
Yuting Lan
Yuting Lan
Runchen Wang
Runchen Wang
Zhexue Hao
Zhexue Hao
Hongsheng Deng
Hongsheng Deng
Shen Zhao
Shen Zhao
Bo Cheng
Bo Cheng

Translational lung cancer research, pp. 188-203, 2020.

Cited by: 0|Bibtex|Views12|Links
WOS
Keywords:
PD-1/L1 inhibitorsfront-linenetwork meta-analysis (NMA)non-small cell lung cancer (NSCLC)

Abstract:

We conducted a systematic comparison of first line immunotherapy for advanced NSCLC. Chemo-immunotherapies were better than chemotherapy and mono-immunotherapies in most patients. Pembrolizumab might have better efficacy than other PD-1/L1 inhibitors.

Code:

Data:

Your rating :
0

 

Tags
Comments